semaglutide immunoassay fda cleared assay ELISA FDA issues warning about some

A significant 'biosimilar void' exists, where many biologics losing patent protection lack biosimilars in development due to factors like sales potential, manufacturing complexity, and regulatory hurdles

3.1.1 Mechanism In the large intestine, intestinal bacteria can contribute to energy production through the fermentation of indigestible food ingredients [24]

Real-world safety profile of once-weekly semaglutide in people with type 2 diabetes: analysis of pooled data from the SemaglUtide Real-world Evidence (SURE) programme

Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and LEADER (comparative analysis of GLP-1 cardiovascular outcome trials)

"But even if people get surgery or [get on] the Ozempic craze, Im like, 'Who cares!' As long as people feel good about themselves, who am I to judge